CMP 001 - CAMP4 Therapeutics
Alternative Names: CMP-001 - CAMP4 Therapeutics; CMP-CPS-001Latest Information Update: 26 Nov 2025
At a glance
- Originator CAMP4 Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action Carbamoyl phosphate synthase (ammonia) expression stimulants
-
Orphan Drug Status
Yes - Inborn urea cycle disorders
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Inborn urea cycle disorders
Most Recent Events
- 26 Nov 2025 CMP 001 - CAMP4 Therapeutics is available for licensing as of 07 Nov 2025. http://www.camp4tx.com
- 07 Nov 2025 CAMP4 Therapeutics receives Clinical Trial Application (CTA) approval from the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands
- 07 Nov 2025 Adverse event, pharmacokinetics and pharmacodynamics data from phase I trial in Inborn urea cycle disorders released by CAMP4 Therapeutics